


1614



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mel H. Epstein, Kjesten A. Wiig and Jeroen Verheijen

Application No.: 10/791,223

Group Art Unit: 1614

Filed: March 2, 2004

Examiner: Not assigned

Confirmation No.: 3953

Title: Methods for Treating Mild Cognitive Impairment and Alzheimer's Disease

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
June 22, 2006	Patricia L. Hillery
Date	Signature
Patricia L. Hillery	
Typed or printed name of person signing certificate	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37-CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application file.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
 - ☒ Copies of the cited references are enclosed.
 - ☐ Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
 - ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
 - ☒ The listed references (A5, A14, A17, A26, B1, B3, B4, B5, B6, B7, B8, B10, C13, C82, C86, C117, C169, C173, C187, C190, C192, C223, C228, C255 and C261) were cited in the enclosed International Search Reports in related foreign applications.
 - ☒ The "concise explanation" requirement (non-English references) for reference B1 under 37 CFR 1.98(a)(3) is satisfied by:
 - ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☒ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action and related English language patent (A3)
 - ☐ the enclosed English language abstract.

- [X] Applicant requests that the following non-published pending applications be considered:
(Affix a label or apply the stamp "Non-Published IDS Reference - Do Not Scan" to the front of each unpublished pending appl'n.)

Examiner's
Initials

____ U.S. Patent Application No. 11/133,144, by Mel H. Epstein, Kjesten A. Wiig and Randall L. Carpenter, filed May 19, 2005, Docket No.: 3474.1001-014.

____ U.S. Patent Application No. 10/557,095, by Mel H. Epstein, Kjesten A. Wiig, Randall L. Carpenter, Peter Zarevics and H. Moore Arnold, filed November 17, 2005, Docket No.: 3474.1001-018.

____ U.S. Patent Application No. 11/305,495, by Mel H. Epstein and Kjesten A. Wiig, filed December 15, 2005, Docket No.: 3474.1001-020.

____ U.S. Patent Application No. 11/303,633, by Mel H. Epstein and Kjesten A. Wiig, filed December 15, 2005, Docket No.: 3474.1001-021.

Examiner

Date

- [X] A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.
- [] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.


Method of payment:

- [] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By


 Mary K. Murray
 Registration No.: 47,813
 Telephone: (978) 341-0036
 Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

June 22, 2006

449 REPRODUCED


**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

June 19, 2006

(Use several sheets if necessary)

 ATTORNEY DOCKET NO.
3474.1001-011

 APPLICATION NO.:
10/791,223

 FIRST NAMED INVENTOR
Mel H. Epstein

 FILING DATE
March 2, 2004

 EXAMINER
Not assigned

 CONFIRMATION NO.
3953

 GROUP
1614

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A1	2002/0066457	06-06-2002	Landfield, <i>et al.</i>
	A2	2,828,343	03-25-1958	Tindall, J. B.
	A3	3,728,445	04-17-1973	Bardani
	A4	3,996,381	12-07-1976	Florvall, <i>et al.</i>
	A5	4,034,113	07-05-1977	Shulgin
	A6	4,105,695	08-08-1978	Partyka, R. A., <i>et al.</i>
	A7	4,479,932	10-30-1984	Bodor, N. S.
	A8	4,598,094	07-01-1986	Wurtman, R. J., <i>et al.</i>
	A9	4,636,494	06-13-1987	Growdon, J. H., <i>et al.</i>
	A10	4,647,591	03-03-1987	Cherkin, <i>et al.</i>
	A11	5,019,594	05-28-1991	Wurtman, R. J., <i>et al.</i>
	A12	5,075,338	12-24-1991	Knoll, <i>et al.</i>
	A13	5,096,712	03-17-1992	Wurtman, R. J.
	A14	5,151,449	09-29-1992	Milgram
	A15	5,220,068	06-15-1993	Knoll, <i>et al.</i>
	A16	5,225,446	07-06-1993	Milgram
	A17	5,422,355	06-06-1995	White, <i>et al.</i>
	A18	5,684,018	11-04-1997	Alexander, J.
	A19	5,914,129	06-22-1999	Mauskop, A.
	A20	6,204,245 B1	03-20-2001	Siegel, J. M., <i>et al.</i>
	A21	6,228,875 B1	05-08-2001	Tsai, G., <i>et al.</i>
	A22	6,251,938 B1	06-26-2001	Chorev, M., <i>et al.</i>
	A23	6,284,760 B1	09-04-2001	Marston, H. M., <i>et al.</i>
	A24	6,451,806	09-17-2002	Farrar
	A25	6,492,427 B2	12-10-2002	Shankar, <i>et al.</i>
	A26	6,635,675 B2	10-21-2003	Kranzler, <i>et al.</i>

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

June 19, 2006

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
3474.1001-011

APPLICATION NO.:
10/791,223

FIRST NAMED INVENTOR
Mel H. Epstein

FILING DATE
March 2, 2004

EXAMINER
Not assigned

CONFIRMATION NO.
3953

GROUP
1614

FOREIGN PATENT DOCUMENTS

[illegible]

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Alafuzoff, I., <i>et al.</i> , "Selegiline Treatment and the Extent of Degenerative Changes in Brain Tissue of Patients with Alzheimer's Disease," <i>Eur. J. Clin. Pharmacol.</i> , 55:815-819 (2000).
C2	Alles, G. A., "Comparative Physiological Actions of the Optically Isomeric Phenisopropylamines," <i>University of California Publications in Pharmacology</i> , 129-150 (1939).
C3	Angrist, and Gershon, "Relationship Between Symptoms and Urinary Levels of Amphetamine," <i>Some Recent Studies of Amphetamine Psychosis - Unresolved Issues</i> , 197-203.
C4	Angrist, B. M., <i>et al.</i> , "Comparative Psychotomimetic Effects of Stereoisomers of Amphetamine," <i>Nature</i> , 234:152-153 (1971).
C5	Anisman, H. and Waller, T. G., "Effects of Methamphetamine and Shock Duration During Inescapable Shock Exposure on Subsequent Active and Passive Avoidance," <i>J. Comp. Physiol. Psychol.</i> , 77(1):143-151 (1971).
C6	Arakawa, O., "Effects of Methamphetamine and Methylphenidate on Single and Paired Rat Open-Field Behaviors," <i>Physiol. Behav.</i> , 55(3):441-446 (1994).
C7	Arnold, L. E., "Levoamphetamine vs Dextroamphetamine in Minimal Brain Dysfunction," <i>Arch. Gen. Psychiatry</i> , 33:292-301 (1976).
C8	Arnold, L. E., "Levoamphetamine and Dextroamphetamine: Comparative Efficacy in the Hyperkinetic Syndrome," <i>Arch. Gen. Psychiat.</i> , 27:816-822 (1972).
C9	Axelrod, J., "Amphetamine: Metabolism, Physiological Disposition and Its Effects on Catecholamine Storage," <i>Amphetamines and Related Compounds</i> , 207-216 (1970).
C10	Axelrod, J., "The Enzymatic Deamination of Amphetamine (Benzedrine)," <i>Laboratory of Chemical Pharmacology</i> , 753-763 (1954).
C11	Axelrod, J., <i>et al.</i> , "Effect of Psychotropic Drugs on the Uptake of H ³ -Norepinephrine by Tissues," <i>Science</i> , 133:383-384 (1961).
C12	Balster, R. L., <i>et al.</i> , "A Comparison of <i>d</i> -Amphetamine, <i>l</i> -Amphetamine, and Methamphetamine Self-administration in Rhesus Monkeys," <i>Pharm. Biochem. Behav.</i> , 1:67-71 (1973).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C13	Barch, D. M., <i>et al.</i> , "The Effects of D-Amphetamine on Language Function in Schizophrenia," <i>Society for Neuroscience Abstracts</i> 23(1-2):p. 1952 (1997).	
C14	Bartus, R. T., "Drugs to Treat Age-Related Neurodegenerative Problems," <i>JAGS</i> , 38(6):680-695 (1990).	
C15	Bartzokis, G., <i>et al.</i> , "Selegiline Effects on Cocaine-Induced Changes in Medial Temporal Lobe Metabolism and Subjective Ratings of Euphoria," <i>Neuropsychopharmacology</i> , 20(6): 582-590 (1999).	
C16	Batterman, R.C., "Studies with Levo-Desoxyephedrine," Combination Report to the Vicks Chemical Company, March 4, 1965.	
C17	Bauer, R. and Evey, L., "Differential Effects of L-Amphetamine on Ontogeny of Active Avoidance, Intertitial Responses, and Locomotor Activity," <i>Psychopharmacology</i> 75: 299-304 (1981).	
C18	Beckett, A. H. and Rowland, M., "Urinary Excretion Kinetics of Amphetamine in Man," <i>J. Pharm. Pharmacol.</i> 17:628-639 (1965).	
C19	Beckett, A. M., <i>et al.</i> , "Metabolic Oxidation on Aliphatic Basic Nitrogen Atoms and Their α -carbon Atoms-Some Unifying Principles," <i>Letters to the Editor, J. Pharm. Pharmac.</i> 23:809-812 (1971).	
C20	Berlyne, D. E., "Arousal, Reward and Learning," <i>Ann. N. Y. Acad. Sci.</i> , 159(3):1059-1070 (1969).	
C21	Biel, J. H., "Structure-Activity Relationships of Amphetamine and Derivatives," <i>Amphetamines and Related Compounds</i> , 3-19 (1970).	
C22	Biel, J. H. and Bopp, B. A., "Amphetamines: Structure-Activity Relationships," in <i>The Handbook of Psychopharmacology</i> , Vol. 11, stimulants, L. L. Iversen, S. D. Iverson. and S. H. Snyder. Eds.. Plenum Publishing Company, New York, 1978, pp. 1-39.	
C23	Birkmayer, W., "Long Term Treatment With L-Deprenyl," <i>J. Neural Transm.</i> , 43:239-244 (1978).	
C24	Birks, J. and Flicker, L., "Selegiline For Alzheimer's Disease," (Cochrane Review). In: <i>The Cochrane Library, Issue 2</i> (2002). Oxford: Update Software.	
C25	Bisagno, V., <i>et al.</i> , "Short Toxic Methamphetamine Schedule Impairs Object Recognition Task in Male Rats," <i>Brain Res.</i> , 940:95-101 (2002).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C26	Bishop, J., <i>et al.</i> , "Toxicology and Carcinogenesis Studies of <i>dl</i> -Amphetamine Sulfate in F344/N Rats and B6C3F ₁ Mice," (Technical Report Series No. 387). Research Triangle Park, NC: National Toxicology Program, U. S. Department of Health and Human Services (1991).	
C27	Blaug, S. M. and Huang W.-T., "Interaction of Dextroamphetamine Sulfate with Spray-Dried Lactose," <i>J. Pharm. Sci.</i> , 61(11):1770-1775 (1972).	
C28	Bodkin, J. A. and Amsterdam, J. D., "Transdermal Selegiline in Major Depression: A Double-Blind, Placebo-Controlled, Parallel-Group Study in Outpatients," <i>Am. J. Psychiatry</i> , 159(11):1869-1875 (2002).	
C29	Brandeis, R. <i>et al.</i> , "Improvement of Cognitive Function by MAO-B Inhibitor L-Deprenyl in Aged Rats," <i>Pharmacol. Biochem. Behav.</i> , 39:297-304 (1991).	
C30	Bromage, P. R., "Comparison of Vasoactive Drugs in Man," <i>Bri. Med. J.</i> , 72-74 (July 12, 1952).	
C31	Brown, G. L., "Plasma Levels of <i>d</i> -Amphetamine in Hyperactive Children," <i>Psychopharmacology</i> , 62:133-140 (1979).	
C32	Brown, R. W., <i>et al.</i> , "D-amphetamine Facilitation of Morris Water Task Performance is Blocked by Eticlopride and Correlated with Increased Dopamine Synthesis in the Prefrontal Cortex," <i>Behav. Brain Res.</i> , 114:135-143 (2000).	
C33	Browne, R. G. and Segal, D. S., "Metabolic and Experiential Factors in the Behavioral Response to Repeated Amphetamine," <i>Pharmacol. Biochem. Behav.</i> , 6:545-552 (1977).	
C34	Burešová, O. and Bureš, J., "Radial Maze as a Tool for Assessing the Effect of Drugs on the Working Memory of Rats," <i>Psychopharmacology</i> , 77:268-271 (1982).	
C35	CA Index Name: "Benzeneethanamine, α -methyl-, (α S)-(9Cl)", <i>SciFinder Scholar</i> , Registry Number: 51-64-9 (1p.) (2001).	
C36	Caldwell, J., <i>et al.</i> , "Metabolism of [¹⁴ C]Methamphetamine in Man, the Guinea Pig and the Rat," <i>Biochem. J.</i> , 129:11-22 (1972).	
C37	Cappon, G. D. and Vorhees, C. V., "Plasma and Brain Methamphetamine Concentrations in Neonatal Rats," <i>Neurotoxicol. Teratol.</i> , 23:81-88 (2001).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011	APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein	FILING DATE March 2, 2004	
	EXAMINER Not assigned	CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C38	Carr, G. D. and White, N. M., "The Relationship Between Stereotypy and Memory Improvement Produced by Amphetamine," <i>Psychopharmacology</i> 82:203-209 (1984).
C39	Chang, L., <i>et al.</i> , "Perfusion MRI and Computerized Cognitive Test Abnormalities in Abstinent Methamphetamine Users," <i>Psychiatry Research Neuroimaging</i> , 114:65-79 (2002).
C40	Chapman, D. E., <i>et al.</i> , "Long-Term Changes in Basal Ganglia Function After a Neurotoxic Regimen of Methamphetamine," <i>J. Pharmacol. Exp. Ther.</i> , 296(2):520-527 (2001).
C41	Cho, D., <i>et al.</i> , "Behavioral Teratogenicity of Methamphetamine," Department of Toxicology, National Institute of Safety Research, Seoul, Korea., <i>Journal Toxicol. Sci.</i> , 16 (Supp. 1):37-49 (1991).
C42	Chrisp, P., <i>et al.</i> , "Selegiline: A Review of its Pharmacology, Symptomatic Benefits and Protective Potential in Parkinson's Disease," <i>Drugs & Aging</i> , 1(3):228-248 (1991).
C43	Clement, B., <i>et al.</i> , "Reduction of Amphetamine Hydroxylamine and Other Aliphatic Hydroxylamines by Benzamidoxime Reductase and Human Liver Microsomes," <i>Chem. Res. Toxicol.</i> , 13:1037-1045 (2000).
C44	Cochran, J. C., <i>et al.</i> , "Parsing Attentional Components During a Simple Reaction Time Task Using Sleep Deprivation and Amphetamine Intervention," <i>Precet. Mot. Skills</i> , 75:675-689 (1992).
C45	Cochran, J. C., <i>et al.</i> , "Decoupling Motor Memory Strategies: Effects of Sleep Deprivation and Amphetamine," <i>Intern. J. Neurosci.</i> , 74:45-54 (1994).
C46	Cody, J. T. and Schwarzhoff, R., "Interpretation of Methamphetamine and Amphetamine Enantiomer Data," <i>J. Anal. Toxicol.</i> , 17:321-326 (October, 1993).
C47	Cody, J. T., "Metabolic Precursors to Amphetamine and Methamphetamine," <i>Forensic Sci. Rev.</i> , 5(2):110-127 (1993).
C48	Comer, S. D., <i>et al.</i> , "Effects of Repeated Oral Methamphetamine Administration in Humans," <i>Psychopharmacology</i> , 155:397-404 (2001).
C49	Cook, C. E., <i>et al.</i> , "Pharmacokinetics of Oral Methamphetamine and Effects of Repeated Daily Dosing in Humans," <i>Drug Metab. Dispos.</i> , 20(6):856-862 (1992).
C50	Cook, C. E., <i>et al.</i> , "Pharmacokinetics of Methamphetamine Self-Administered to Human Subjects by Smoking S-(+)-Methamphetamine Hydrochloride," <i>Drug Metab. Dispos.</i> , 21(4):717-723 (1993).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C51	Cooke, B. J. A., "Chirality of Methamphetamine and Amphetamine From Workplace Urine Samples," <i>J. Anal Toxicol.</i> , 18:49-51 (1994).
C52	Cookson, J. and Silverstone, T., "The Effects of Methamphetamine on Mood and Appetite in Depressed Patients: A Placebo-controlled Study," <i>Int. Clin. Psychopharmacol.</i> , 1:127-133 (1986).
C53	Corsi-Cabrera, M., <i>et al.</i> , "Gender Differences in the EEG During Cognitive Activity," <i>Intern. J. Neurosci.</i> 72:257-264 (1993).
C54	Courtney, K. D. and Valerio, D.A., "Teratology in the <i>Macaca mulatta</i> ," <i>Teratology</i> , 1:163-172 (1968).
C55	Crabbe, J. C. and Alpern, H. P., "d-Amphetamine: Disruptive Effects on the Long-Term Store of Memory and Proactive Facilitatory Effects on Learning in Inbred Mice," <i>Pharmacol. Biochem. Behav.</i> , 3:647-652 (1975).
C56	Croce, P. D., <i>et al.</i> , "A Simple Procedure for N-Propenylation and N-Propynylation of Secondary Amines," <i>Gazzetta Chimica Italiana</i> , 126:107-109 (1996).
C57	Csanda, E., <i>et al.</i> , "Experiences With L-Deprenyl in Parkinsonism," <i>J. Neural Transm.</i> , 43:263-269 (1978).
C58	Czub, M., <i>et al.</i> , "Effects of Selegiline in a Retroviral Rat Model for Neurodegenerative Disease," <i>J. NeuroVirol.</i> , 5:458-464 (1999).
C59	Davis, J. M., <i>et al.</i> , "Effects of Urinary pH on Amphetamine Metabolism," <i>Ann. N.Y. Acad. Sci.</i> , 179:493-501 (1971).
C60	DeLuca, J., "Cognitive Dysfunction After Aneurysm of the Anterior Communicating Artery," <i>J. Clin. Exp. Neuropsychol.</i> , 14(6):924-934 (1992).
C61	Dixit, S. N., <i>et al.</i> , "Effect of Selegiline on Cognitive Functions in Parkinson's Disease," <i>JAPI</i> , 47(8):784-786 (1999).
C62	Donnan, P. T., <i>et al.</i> , "Selegiline and Mortality in Subjects with Parkinson's Disease: a Longitudinal Community Study," (Reply from the authors), <i>Neurology</i> , 57(2): Correspondence (2001).
C63	Dring, L. G., <i>et al.</i> , "The Metabolic Fate of Amphetamine in Man and Other Species," <i>Biochem. J.</i> , 116:425-435 (1970).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C64	Dring, L. G., <i>et al.</i> , "The Fate of Amphetamine in Man and Other Mammals," <i>Letters to the Editor, J. Pharm. Pharmac.</i> 18:402-405 (1966).
C65	Dringenberg, H. C., <i>et al.</i> , "Increased Effectiveness of Tacrine by Deprenyl Co-treatment in Rats: EEG and Behavioral Evidence," <i>Neuropharmacology and Neurotoxicology</i> , 11(16):3513-3516 (2000).
C66	Ebadi, M., <i>et al.</i> , "Neuroprotective Actions of Selegiline," <i>J. Neurosc. Res.</i> , 67:285-289 (2002).
C67	Ebert, U. and Kirch, W., "Scopolamine Model of Dementia: Electroencephalogram Findings and Cognitive Performance," <i>Eur. J. Clin. Invest.</i> , 28:944-949 (1998).
C68	Elsworth, J. D., <i>et al.</i> , "The Contribution of Amphetamine Metabolites of (-)-Deprenyl to Its Antiparkinsonian Properties," <i>J. Neural Transm.</i> , 54:105-110 (1982).
C69	Ernst, M., <i>et al.</i> , "Selegiline in ADHD Adults: Plasma Monoamines and Monoamine Metabolites," <i>Neuropsychopharmacology</i> , 16(4):276-284 (1997).
C70	Ernst, M., <i>et al.</i> , "Selegiline in Adults With Attention Deficit Hyperactivity Disorder: Clinical Efficacy and Safety," <i>Psychopharmacol. Bull.</i> , 32(3):327-334 (1996).
C71	Falsaperla, A., <i>et al.</i> , "Selegiline Versus Oxiracetam in Patients With Alzheimer-Type Dementia," <i>Clinical Therapeutics</i> , (12)5:376-384, (1990).
C72	Fang, J. and Yu, P. H., "Effect of L-Deprenyl, its Structural Analogues and Some Monoamine Oxidase Inhibitors on Dopamine Uptake," <i>Neuropharmacology</i> , 33(6):763-768 (1994).
C73	Ferrando, R. L., <i>et al.</i> , "Bizarre Behavior Following the Ingestion of Levo-Desoxyephedrine," <i>Drug Intelligence and Clinical Pharmacy</i> , 22:214-216 (1988).
C74	Filip, V. and Kolibas, E., "Selegiline in the Treatment of Alzheimer's Disease: a Long-Term Randomized Placebo-Controlled Trial," <i>J. Psychiatry Neurosci.</i> , 24(3):234-243 (1999).
C75	Finali, G., <i>et al.</i> , "L-Deprenyl Therapy Improves Verbal Memory in Amnesic Alzheimer Patients," <i>Clin. Neuropharmacol.</i> , 14(6):523-536 (1991).
C76	Finali, G., <i>et al.</i> , "Alzheimer-type Dementia and Verbal Memory Performances: Influence of Selegiline Therapy," <i>Ital. J. Neurol. Sci.</i> , 13:141-148 (1992).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C77	Finkelstein, J. E., <i>et al.</i> , "Milacemide Treatment in Mice Enhances Acquisition of a Morris-Type Water Maze Task," <i>Pharmacol. Biochem. Behav.</i> , 49(3):707-710 (1994).	
C78	Fitzgerald, R. L., <i>et al.</i> , "Resolution of Methamphetamine Stereoisomers in Urine Testing: Urinary Excretion of R(-)-Methamphetamine Following Use of Nasal Inhalers," <i>J. Anal. Toxicol.</i> , 12:255-259 (Sept-Oct. 1988).	
C79	Fleming, K., <i>et al.</i> , "Neuropsychological Effects of Amphetamine May Correlate with Personality Characteristics," <i>Psychopharmacol. Bull.</i> , 31(2):357-362 (1995).	
C80	Foster, B. S. and Gilbert, D. D., "Enantiomeric Determination of Amphetamine and Methamphetamine in Urine by Precolumn Derivatization with Marfey's Reagent and HPLC," <i>J. Anal. Toxicol.</i> , 22:265-269 (1998).	
C81	Fowler, J. S., <i>et al.</i> , "Evidence That L-deprenyl Treatment for One Week Does Not Inhibit MAO A or the Dopamine Transporter in the Human Brain," <i>Life Sci.</i> , 68:2759-2768 (2001).	
C82	Gelowitz, D. L., <i>et al.</i> , "Chronic L-Deprenyl or L-Amphetamine: Equal Cognitive Enhancement, Unequal MAO Inhibition," <i>Pharmacol. Biochem. Behav.</i> , 47:41-45 (1994).	
C83	Gibbs, M. E., "Effects of Amphetamine on Short-Term, Protein-Independent, Memory in Day-Old Chickens," <i>Pharmacol. Biochem. Behav.</i> , 4:305-309 (1976).	
C84	Glennon, R. A., <i>et al.</i> , "A Preliminary Behavioral Investigation of PMMA, the 4-Methoxy Analog of Methamphetamine," <i>Pharmacol. Biochem. Behav.</i> , 31:9-13 (1988).	
C85	Golbe, L. I., <i>et al.</i> , "Selegiline and Parkinson's Disease: Protective and Symptomatic Considerations," <i>Drugs</i> , 39(5):646-651 (1990).	
C86	Gold, P. E., <i>et al.</i> , "Modulation of Long-Term Potentiation by Peripherally Administered Amphetamine and Epinephrine," <i>Brain Res.</i> , 305:103-107 (1984).	
C87	Goldstein, L. B., "Effects of Amphetamines and Small Related Molecules on Recovery After Stroke in Animals and Man," <i>Neuropharmacology</i> 39:852-859 (2000).	
C88	Gordon, M. N., <i>et al.</i> , "Oral Versus Transdermal Selegiline: Antidepressant-Like Activity in Rats," <i>Pharmacol. Biochem. Behav.</i> , 63(3):501-506 (1999).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C89	Grasing, K., <i>et al.</i> , "Biphasic Effects of Selegiline on Striatal Dopamine: Lack of Effect on Methamphetamine-Induced Dopamine Depletion," <i>Neurochem. Res.</i> , 26(1):65-74 (2001).
C90	Gunaratna, C. and Kissinger, P. T., "Investigation of Stereoselective Metabolism of Amphetamine in Rat Liver Microsomes by Microdialysis and Liquid Chromatography with Precolumn Chiral Derivatization," <i>J. Chromatography A</i> , 828:95-103 (1998).
C91	Gunne, L-M., "The Urinary Output of <i>d</i> - and <i>l</i> -Amphetamine in Man," <i>Biochem. Pharmacol.</i> , 16:863-869 (1967).
C92	Gyarmati, Z. S., <i>et al.</i> , "Behavioural Consequences of Methamphetamine-Induced Neurotoxicity in Rats," <i>Neurobiology</i> , 9(1):37-39 (2001).
C93	Haley, T. J., "Desoxyephedrine—A Review of the Literature," <i>J. Am. Pharm. Assoc.</i> , 36(6):161-169 (1947).
C94	Hardman, J.G., <i>et al.</i> , "Goodman & Gilman's The Pharmacological Basis of Therapeutics," 9 th Edition eds. (NY: McGraw-Hill), pages 202 and 221 (1995).
C95	Harris, H., <i>et al.</i> , "Behavioral Properties of Amphetaminil Enantiomers," National Institute of Mental Health - 42 nd Annual NCDEU Meeting: Poster Session I [online], July 2002 [retrieved on 2003-03-11]. Retrieved from the Internet <URL: http://www.nimh.nih.gov/ncdeu/abstracts2002/ncdeu1025.cfm >.
C96	Hart, C. L., <i>et al.</i> , "Methamphetamine Self-administration by Humans," <i>Psychopharmacology</i> , 157:75-81 (2001).
C97	Hartmann, E. and Cravens, J., "Sleep: Effects of <i>d</i> - and <i>l</i> -Amphetamine in Man and in Rat," <i>Psychopharmacology</i> , 50:171-175 (1976).
C98	Haughey, H. M., <i>et al.</i> , "Differential Effects of Methamphetamine on NA ⁺ /Cl ⁻ Dependent Transporters," <i>Brain Res.</i> , 863:59-65 (2000).
C99	Haycock, J. W., <i>et al.</i> , "Effects on Retention of Posttraining Amphetamine Injections in Mice: Interaction with Pretraining Experience," <i>Psychopharmacology</i> , 54:21-24 (1977).
C100	Heinonen, E. H., <i>et al.</i> , "Pharmacokinetic Aspects of <i>l</i> -deprenyl (Selegiline) and its Metabolites," <i>Clin. Pharmacol. Ther.</i> 56(6), part 2, 742-749 (1994).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned	CONFIRMATION NO. 3953	GROUP 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C101	Heinonen, E. H., <i>et al.</i> , "Pharmacokinetics and Metabolism of Selegiline," <i>Acta Nerol Scand.</i> , 126:93-99 (1989).	
C102	Herrell, J. M., <i>et al.</i> , "A Multisite Study of the Effectiveness of Methamphetamine Treatment: An Initiative of the Center for Substance Abuse Treatment," <i>J. Psychoactive Drugs</i> , 32(2):143-147 (2000).	
C103	Hornbeck, C. L. and Czarney, R. J., "Retrospective Analysis of Some L-Methamphetamine/L-Amphetamine Urine Data," <i>J. Anal Toxicol.</i> , 17:23-25 (1993).	
C104	Hutchaleelaha, A., <i>et al.</i> , "Disposition Kinetics of <i>d</i> - and <i>l</i> -Amphetamine Following Intravenous Administration of Racemic Amphetamine to Rats," <i>Drug Metab. Dispos.</i> , 22(3):406-411 (1994).	
C105	Itoh, J., <i>et al.</i> , "Utility of an Elevated Plus-Maze for Dissociation of Amnesic and Behavioral Effects of Drugs in Mice," <i>Eur. J. Pharmacol.</i> , 194:71-76 (1991).	
C106	Jelic, V., <i>et al.</i> , "Quantitative Electroencephalography in Mild Cognitive Impairment: Longitudinal Changes and Possible Prediction of Alzheimer's Disease," <i>Neurobiol. of Aging</i> , 21:533-540 (2000).	
C107	Jirovsky, D., <i>et al.</i> , "Methamphetamine - Properties and Analytical Methods of Enantiometer Determination," <i>Forensic Sci. Int.</i> , 96:61-70 (1998).	
C108	Jirovsky, D., <i>et al.</i> , "The Pilot Study of Methamphetamine Enantiometer Metabolism in Man by Capillary Electrophoresis," <i>Chemica</i> , 40:25-34 (2001).	
C109	Johnson, B. A., <i>et al.</i> , "Effects of Isradipine, A Dihydropyridine-Class Calcium Channel Antagonist, on D-Methamphetamine-Induced Cognitive and Physiological Changes in Humans," <i>Neurophychopharmacology</i> , 22(5):504-512 (2000).	
C110	Jonason, K. R., <i>et al.</i> , "Effects of Amphetamine Upon Relearning Pattern and Black-White Discriminations Following Neocortical Lesions in Rats," <i>J. Comp. Physiol. Psychol.</i> , 73(1):47-55 (1969).	
C111	Jori, A., <i>et al.</i> , "Differences in the Availability of <i>d</i> - and <i>l</i> -Enantiomers after Administration of Racemic Amphetamine to Rats," <i>Xenobiotica</i> , 8(10):589-595 (1978).	
C112	Karch, S. B., <i>et al.</i> , "Methamphetamine-Related Deaths in San Francisco: Demographic, Pathologic, and Toxicologic Profiles," <i>J. Forensic Sci.</i> , 44(2):359-368 (1999).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned	CONFIRMATION NO. 3953	GROUP 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C113	Karoum, F., <i>et al.</i> , "Metabolism of (-) Deprenyl to Amphetamine and Methamphetamine May Be Responsible for Deprenyl's Therapeutic Benefit: a Biochemical Assessment," <i>Neurology (Ny)</i> , 32:503-509 (1982).
C114	Kasirsky, G. and Tansy, M.F., "Teratogenic Effects of Methamphetamine in Mice and Rabbits," <i>Teratology</i> , 4:131-134 (1971).
C115	Kieburtz, K., <i>et al.</i> , "A Randomized, Double-Blind, Placebo-Controlled Trial of Deprenyl and Thioctic Acid in Human Immunodeficiency Virus-Associated Cognitive Impairment," <i>Neurology</i> , 50:645-651 (1998 March).
C116	Kikuchi, M., <i>et al.</i> , "EEG Changes Following Scopolamine Administration in Healthy Subjects," <i>Neuropsychobiology</i> 39:219-226 (1999).
C117	Kim, E. M., <i>et al.</i> , "Determination of Enantiomeric Metabolites of L-deprenyl, d-methamphetamine, and Racemic Methamphetamine in Urine by Capillary Electrophoresis: Comparison of Deprenyl Use and Methamphetamine Use," <i>J. Anal Toxicol.</i> , 24(4):238-244 (2000).
C118	Kirrane <i>et al.</i> , "Effects of Amphetamine on Visuospatial Working Memory Performance in Schizophrenia Spectrum Personality Disorder," <i>Neuropsychopharmacology</i> 2000 22(1):14-18 (2000).
C119	Knoefel, P., "The Influence of Phenisopropyl Amine and Phenisopropyl Methyl Amine on Work Output," <i>Society for Pharmacol. Exp. Ther.</i> , page 83 (1943).
C120	Knoll, J., "The Possible Mechanisms of Action of (-)Deprenyl in Parkinson's Disease," <i>J. Neural Transm.</i> , 43:177-198 (1978).
C121	Knoll, J., "The Pharmacology of (-)Deprenyl," <i>J. Neural Transm., (Suppl)</i> , 22:75-89 (1986).
C122	Kohl, R. L., <i>et al.</i> , "Arousal and Stability: The Effects of five New Sympathomimetic Drugs Suggest a New Principle for the Prevention of Space Motion Sickness," <i>Aviat. Space, Environ. Med.</i> , 137-143 (1986).
C123	Kopell, B. S., <i>et al.</i> , "The Effects of Methamphetamine and Secobarbital on the Continent Negative Variation Amplitude," <i>Psychopharmacologia (Berl.)</i> , 34:55-62 (1974).
C124	Kopell, B. S. and Wittner, W. K., "The Effects of Chlorpromazine and Methamphetamine on Visual Signal-From-Noise Detection," <i>J. Nerv. Ment. Dis.</i> , 147(4):418-424 (1968).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned	CONFIRMATION NO. 3953	GROUP 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C125	Kraemer, T. and Maurer, H. H., "Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives," <i>Ther. Drug Monit.</i> , 24(2):277-289 (2002).	
C126	Kraemer, T. and Maurer, H. H., "Determination of Amphetamine, Methamphetamine and Amphetamine-derived Designer Drugs or Medicaments in Blood and Urine," <i>J. Chromatogr. B.</i> , 713:163-187 (1998).	
C127	Krivanek, J. A. and McGaugh, J. K., "Facilitation Effects of Pre- and Posttrial Amphetamine Administration on Discrimination Learning in Mice," <i>Agents and Actions</i> , 1:36-42 (1969).	
C128	Kuczenski, R., <i>et al.</i> , "Hippocampus Norepinephrine, Caudate Dopamine and Serotonin, and Behavioral Responses to the Stereoisomers of Amphetamine and Methamphetamine," <i>J. Neurosci.</i> , 15(2):1308-1317 (1995).	
C129	Kuhn, D. M., and Geddes, T. J., "Molecular Footprints and Neurotoxic Amphetamine Action," <i>Ann. N. Y. Acad. Sci.</i> , 914:92-103 (2000).	
C130	Kulig, B. M., and Calhoun, W. H., "Enhancement of Successive Discrimination Reversal Learning by Methamphetamine," <i>Psychopharmacologia (Berl.)</i> , 27:233-240 (1972).	
C131	Kumar, V. and Banker, G. S., "Maillard Reaction and Drug Stability," <i>Maillard Reactions in Chemistry, Food, and Health</i> , 151:20-27 (1994).	
C132	Laine, K., <i>et al.</i> , "Multiple-Dose Pharmacokinetics of Selegiline and Desmethylselegiline Suggest Saturable Tissue Binding," <i>Clin. Neuropharmacol.</i> , 23(1):22-27 (2000).	
C133	Lajtha, A., <i>et al.</i> , "Metabolism of (-)-Deprenyl and PF-(-)-Deprenyl in Brain After Central and Peripheral Administration," <i>Neurochem. Res.</i> , 21(10):1155-1160 (1996).	
C134	Larsen, J. P., <i>et al.</i> , "Does Selegiline Modify the Progression of Early Parkinson's Disease? Results from a Five-year Study," <i>Eur. J. Neurol.</i> , 6:539-547 (1999).	
C135	Law, M. Y. L., "Selective Involvement of Cytochrome P450 2D Subfamily in In Vivo 4-Hydroxylation of Amphetamine in Rat," <i>Drug Metab. Dispos.</i> , 28(3):348-353 (2000).	
C136	Law, M. Y. L. and Moody, D. E., "Urinary Excretion of Amphetamine and 4'-Hydroxyamphetamine by Sprague Dawley and Dark Agouti Rats," <i>Life Sci.</i> , 54(15):1073-1079 (1994).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned	CONFIRMATION NO. 3953	GROUP 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C137	Lee, E. H. Y. and MA, Y. L., "Amphetamine Enhances Memory Retention and Facilitates Norepinephrine Release from the Hippocampus in Rats," <i>Brain Res. Bull.</i> , 37(4):411-416 (1995).
C138	Lehmann, H. E. and Ban, T. A., "Effects of Psychoactive Drugs on Conflict Avoidance Behavior in Human Subjects," <i>Activitas nervosa superior</i> , 13(2):82-85 (1971).
C139	Lehmann, H. E., <i>et al.</i> , "The Effect of Psychostimulants on Psychometric Test Performance With Special Reference to Conflict Avoidance Behavior," <i>Curr. Ther. Res.</i> , 12(6):390-393 (1970).
C140	Lin, L. Y., <i>et al.</i> , "Cytochrome P4502D Isozymes Catalyze the 4-Hydroxylation of Methamphetamine Enantiomers," <i>Drug Metab. Dispos.</i> , 23(6):610-614 (1995).
C141	Lin, J. S., <i>et al.</i> , "Effects of Amphetamine and Modafinil on the Sleep/Wake Cycle During Experimental Hypersomnia Induced by Sleep Deprivation in the Cat," <i>J. Sleep Res.</i> , 9(1):89-96.
C142	Lokiec, F., <i>et al.</i> , "A Comparison of the Kinetics of <i>d</i> - and <i>l</i> -Amphetamine in the Brain of Isolated and Aggregated Rats," <i>Psychopharmacology</i> 58:73-77 (1978).
C143	M'Harzi, M., <i>et al.</i> , "d-Amphetamine Enhances Memory Performance in Rats with Damage to the Fimbria," <i>Physiol. Behav.</i> , 42:575-579 (1988).
C144	Magidson, O.Y., and Garkusha, G.A., "The Synthesis of 2-phenylisopropylamine (phenamine)," <i>Chemical Abstracts</i> 35, 5868 (1941).
C145	Mangoni, A. "Effects of a MAO-B Inhibitor in the Treatment of Alzheimer Disease," <i>Eur Neurol.</i> 31: 100-107 (1991).
C146	Mann, J. J., <i>et al.</i> , "A Controlled Study of the Antidepressant Efficacy and Side Effects of (-)-Deprenyl," <i>Arch. Gen. Psychiatry</i> , 46:45-50 (1989).
C147	Martin, W. R., <i>et al.</i> , "Physiologic, Subjective, and Behavioral Effects of Amphetamine, Methamphetamine, Ephedrine, Phenmetrazine, and Methylphenidate in Man," <i>Clin. Pharmacol. Ther.</i> , 12(2):245-258 (1970).
C148	Martinez, J. L., <i>et al.</i> , "Central and Peripheral Actions of Amphetamine on Memory Storage," <i>Brain Research</i> , 182:157-166 (1980).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C149	Maruyama, W. and Naoi, M., "Neuroprotection by (-)-deprenyl and Related Compounds," <i>Mech. Ageing Dev.</i> , 111:189-200 (1999).	
C150	Matsubara, K., <i>et al.</i> , "L-Deprenyl Prevents the Cell Hypoxia Induced by Dopaminergic Neurotoxins, Mpp+ and β -carbolinium: a Microdialysis Study in Rats," <i>Neuroscience Lett.</i> , 302:65-68 (2001).	
C151	Matthews, C., "Overweight Relapse: Effects of Training and Methamphetamine with Pentobarbital," <i>Curr. Ther. Res.</i> , 12(1):34-39 (1970).	
C152	Mayfield, D. G., "The Effect of Intravenous Methamphetamine on Mood," <i>Int. J. Addict.</i> , 8(3):565-568 (1973).	
C153	McIntyre, H. B., "Computer Analyzed EEG in Amphetamine-Responsive Hyperactive Children," <i>Psychiatry Res.</i> , 4:189-197 (1981).	
C154	Melega, W. P., <i>et al.</i> , "Pharmacokinetic and Pharmacodynamic Analysis of the Actions of D-Amphetamine and D-Methamphetamine on the Dopamine Terminal," <i>J. Pharmacol. Exp. Ther.</i> , 274(1): 90-96 (1995).	
C155	Melega, W. P., <i>et al.</i> , "l-Methamphetamine Pharmacokinetics and Pharmacodynamics for Assessment of <i>in vivo</i> Deprenyl-Derived l-Methamphetamine," <i>J. Pharmacol. Exp. Ther.</i> , 288(2):752-758 (1999).	
C156	Melega, W. P., <i>et al.</i> , "Effects of Deprenyl Metabolite, L-Methamphetamine on Striatal Dopamine Efflux," <i>Neurotransmission, Neuromodulation</i> , A376, Abstract No. 2177.	
C157	Metcalf, F. U., <i>et al.</i> , "Methamphetamine Effects Upon Avoidance Behavior during Limbic Seizures in the Cat," <i>Psychopharmacologia (Berl.)</i> , 21:390-400 (1971).	
C158	Mewaldt, S. P., and Ghoneim, M. M., "The Effects and Interactions of Scopolamine, Physostigmine and Methamphetamine on Human Memory," <i>Pharmacol. Biochem. Behav.</i> , 10:205-210 (1979).	
C159	Milgram, N. W., <i>et al.</i> , "The Effect of L-Deprenyl on Behavior, Cognitive Function, and Biogenic amines in the Dog," <i>Neurochem. Res.</i> , 18(12):1211-1219 (1993).	
C160	Mills, D. and Ledger, R., "The Effects of Oral Selegiline Hydrochloride on Learning and Training in the Dog: A Psychobiological Interpretation," <i>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</i> , 25:1597-1613 (2001).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned	CONFIRMATION NO. 3953	GROUP 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C161	Miyamoto, K., "Conditioned Drug Effects of Pimozide, Haloperidol and Chlorpromazine on Methamphetamine-Induced Behavior," <i>Japanese J. Psychiat. Neurol.</i> , 44(3):629-636 (1990).
C162	Mohs, R. C., <i>et al.</i> , "Sensitivity of Some Human Cognitive Functions to Effects of Methamphetamine and Secobarbital," <i>Drug and Alcohol Depend.</i> , 5:145-150 (1980).
C163	Mohs, R. C., <i>et al.</i> , "Methamphetamine and Diphenhydramine Effects on the Rate of Cognitive Processing," <i>Psychopharmacology</i> , 59:13-19 (1978).
C164	Monmaur, P., <i>et al.</i> , "Involvement of Septal Muscarinic Receptors in Cholinergically Mediated Changes in Rat Rearing Activity," <i>Pharmacol. Biochem. Behav.</i> , 58(2):577-582 (1997).
C165	Moretti, R., <i>et al.</i> , "Effects of Selegiline on Fronto-temporal Dementia: a Neuropsychological Evaluation," <i>Int. J. Geriatr. Psychiatry</i> , 17:391-392 (2002).
C166	Muller, H., <i>et al.</i> , "Rey Auditory-Verbal Learning Test: Structure of a Modified German Version," <i>Journal of Clinical Psychology</i> , 53(7):663-671 (1997).
C167	Munzar, P., <i>et al.</i> , "Potentiation of the Discriminative-stimulus Effects of Methamphetamine by the Histamine H ₃ Receptor Antagonist Thioperamide in Rats," <i>Eur. J. Pharmacol.</i> , 363:93-101 (1998).
C168	Musshoff, F., "Illegal or Legitimate Use? Precursor Compounds to Amphetamine and Methamphetamine," <i>Drug Metab. Rev.</i> , 32(1):15-44 (2000).
C169	Myers, C.E., <i>et al.</i> , "Impaired Delay Eyeblink Classical Conditioning in Individuals With Anterograde Amnesia Resulting From Anterior Communicating Artery Aneurysm Rupture," <i>Behav. Neurosci.</i> , 115(3):560-570 (2001).
C170	Nickel, B., <i>et al.</i> , "Effect of Enantiomers of Deprenyl (Selegiline) and Amphetamine on Physical Abuse Liability and Cortical Electrical Activity in Rats," <i>Neuropharmacology</i> , 29(11):983-992 (1990).
C171	Nicolaus, B. J. R., "Symbiotic Approach to Drug Design," <i>Decision Making in Drug Research</i> , pp. 173-186 (1983).
C172	Ogata, A., "Constitution of Ephedrine," <i>Chemical Abstracts</i> 14, 745 (1920).
C173	Ong, Y. L., <i>et al.</i> , "Suppression of Bulimic Symptoms with Methylamphetamine," <i>Brit. J. Psychiat.</i> , 143: 288-293 (1983).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C174	Ozaki, T., <i>et al.</i> , "The Adverse Effects of l-Methamphetamine on the Development of Explanted Rat Embryos," <i>Asia-Oceania Journal Obstet. Gynaecol.</i> 18(3):277-281 (1992).	
C175	Parkes, J. D., <i>et al.</i> , "Amphetamines in the Treatment of Parkinson's Disease," <i>J. Neurol., Neurosurg., Psychiat.</i> , 38:232-237 (1975).	
C176	Parkes, J. D. and Fenton, G. W., "Levo(-) Amphetamine and Dextro(+) Amphetamine in the Treatment of Narcolepsy," <i>J. Neurol., Neurosurg., Psychiat.</i> , 36:1076-1081 (1973).	
C177	Parkinson Study Group, "Impact of Deprenyl and Tocopherol Treatment on Parkinson's Disease in DATATOP Subjects Not Requiring Levodopa," <i>Ann. Neurol.</i> , 39(1):29-36 (1996).	
C178	Penetar, D. M., <i>et al.</i> , "Amphetamine Effects on Recovery Sleep Following Total Sleep Deprivation," <i>Human Psychopharmacology</i> , 6:319-323 (1991).	
C179	Pepeu, G., "Memory Disorders: Novel Treatments, Clinical Perspective," <i>Life Sci.</i> , 55(25-26):2189-2194 (1994).	
C180	Perez-Reyes, M., <i>et al.</i> , "Clinical Effects of Methamphetamine Vapor Inhalation," <i>Life Sci.</i> , 49(13):953-959 (1991).	
C181	Perez-Reyes, M., "Differences in Sedative Susceptibility Between Types of Depression," <i>Arch. Gen. Psychiat.</i> , 19:64-71 (1968).	
C182	<i>Physician Desk Reference</i> 946, 1221 (1969).	
C183	Pitsikas, N., <i>et al.</i> , "Effect of Org2766, an ACTH(4-9) Analogue, on Recovery After Bilateral Transection of the Fimbria Fornix in the Rat," <i>Pharmacol. Biochem. Behav.</i> , 38:931-934 (1991).	
C184	Pitsikas, N., <i>et al.</i> , "DAU 6215, A Novel 5-HT ₃ Receptor Antagonist, Improves Performance in the Aged Rat in the Morris Water Maze Task," <i>Neurobiol. of Aging</i> 14:561-564 (1993).	
C185	Plaszniak, A. and Kostowski, W., "Effects of p-Bromo-Methamphetamine (V-111) on Conditioned Avoidance Behavior in Rats with Lesioned <i>Raphe Nuclei</i> ," <i>Fol. J. Pharmacol. Pharm.</i> 21, 193-198 (1997).	
C186	Platel, A. and Porsolt, R. D., "Habituation of Exploratory Activity in Mice: A Screening Test for Memory Enhancing Drugs," <i>Psychopharmacology</i> , 78:346-352 (1982).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C187	Prinzmetal, M. and Alles, G. A., "The Central Nervous System Stimulant Effects of Dextro-Amphetamine Sulphate," <i>200(5):665-673 (1940).</i>
C188	Przuntek, H., <i>et al.</i> , "SELEDO: a 5-year Long-term Trial on the Effect of Selegiline in Early Parkinsonian Patients Treated with Levodopa," <i>Eur. J. Neurology</i> , 6:141-150 (1999).
C189	Quartermain, D., <i>et al.</i> , "Amphetamine Enhances Retrieval Following Diverse Sources of Forgetting," <i>Physiol. Behav.</i> , 43:239-241 (1988).
C190	Quartermain, D. and Altman, H. J., "Facilitation of Retrieval by d-Amphetamine Following Anisomycin-Induced Amnesia," <i>Physiol. Psychol.</i> , 10(3):283-292 (1982).
C191	Quartermain, D. and Jung, H., "Persistence of Retrieval Enhancement by Amphetamine Following Scopolamine-Induced Amnesia," <i>Pharmacol. Biochem. Behav.</i> , 33:51-54 (1989).
C192	Quartermain, D., <i>et al.</i> , "Alleviation of Scopolamine Amnesia by Different Retrieval Enhancing Treatments," <i>Pharmacol. Biochem. Behav.</i> 30(4):1093-1096 (1988).
C193	Ramos, J., <i>et al.</i> , "EEG Activity During Cognitive Performance in Women," <i>Intern. J. Neurosci.</i> , 69:185-195 (1993).
C194	Reus, V. I., <i>et al.</i> , "d-Amphetamine: Effects on Memory in a Depressed Population," <i>Biol. Psychol.</i> , 14(2):345-356 (1979).
C195	Reynolds, G. P., <i>et al.</i> , "Deprenyl is Metabolized to Methamphetamine and Amphetamine in Man," <i>Br. J. Clin. Pharmacol.</i> , 6:542-544 (1978).
C196	Richards, J. B., <i>et al.</i> , "Trained and Amphetamine-Induced Circling Behavior in Lesioned, Transplanted Rats," <i>J. Neural Transplantation & Plasticity</i> , 4(2):157-166 (1993).
C197	Richter, D., "CCXXIX. Elimination of Amines in Man," <i>Biochem. J.</i> , 32:1763-1769 (1938).
C198	Richter-Levin, G. and Yaniv, D., "Is LTP in the Hippocampus a Useful Model for Learning-Related Alterations in Gene Expression?," <i>Reviews in Neurosciences</i> , 12:289-296 (2001).
C199	Riederer, P. and Przuntek, H. (eds.), "MAO-B-Inhibitor Selegiline (R-(-)-Deprenyl), A New Therapeutic Concept in the Treatment of Parkinson's Disease," <i>J. Neural Transm., Supp.</i> 25: (1987).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C200	Riederer, P., <i>et al.</i> , "On the Mode of Action of L-Deprenyl in the Human Central Nervous System," <i>J. Neural Transm.</i> , 43:217-226 (1978).
C201	Riekkinen, Jr., P., <i>et al.</i> , "Effects of Alzene and Tacrine on Water Maze Reference and Working Memory Function in Medial Septal-Lesioned Rats," <i>Brain Res.</i> , 714:118-124 (1996).
C202	Riley, D. E., "Reversible Transvestic Fetishism in a Man With Parkinson's Disease Treated With Selegiline," <i>Clin. Neuropharmacol.</i> , 25(4):234-237 (2002).
C203	Riviere, G. J., <i>et al.</i> , "Disposition of Methamphetamine and Its Metabolite Amphetamine in Brain and Other Tissues in Rats after Intravenous Administration," <i>J. Pharmacol. Exp. Ther.</i> , 292(3):1042-1047 (2000).
C204	Riviere, G. J., <i>et al.</i> , "Spontaneous Locomotor Activity and Pharmacokinetics of Intravenous Methamphetamine and Its Metabolite Amphetamine in the Rat," <i>J. Pharmacol. Exp. Ther.</i> , 291(3):1220-1226 (1999).
C205	Roth, L. W., <i>et al.</i> , "A Comparison of the Analeptic, Circulatory and Other Properties of D- and L-Desoxyephedrine," <i>Arch. Int. Pharmacodyn.</i> , XCVII(3):362-368 (1954).
C206	Sainsbury, R. S., "Hippocampal Theta: A Sensory-Inhibition Theory of Function," <i>Neurosc. Biobehav. Rev.</i> , 22(2):237-241 (1998).
C207	Sanders-Bush, E. and Sulser, F., "Metabolic and Neurochemical Aspects of the Pharmacology of Amphetamine and Para-Chloroamphetamine," Chapter 8, pp 69-70.
C208	Sano, M., <i>et al.</i> , "A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease," <i>NEJM</i> , 336(17):1216-1222 (1997).
C209	Sansone, M., <i>et al.</i> , "Interaction between Nootropic Drugs and Methamphetamine on Avoidance Acquisition but not on Locomotor Activity in Mice," <i>Arch. Int. Pharmacodyn.</i> , 278:229-235 (1985).
C210	Sansone, M., <i>et al.</i> , "Minaprine, but not Oxiracetam, Prevents Desipramine-Induced Impairment of Avoidance Learning in Mice," <i>Pol. J. Pharmacol.</i> 47:69-73 (1995).
C211	Sara, S. J. and Deweer, B., "Memory Retrieval Enhanced by Amphetamine After a Long Retention Interval," <i>Behavioral and Neural Biology</i> , 36:146-160 (1982).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned	CONFIRMATION NO. 3953	GROUP 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C212	Sarter, M., "Behavioral Screening for Cognition Enhancers from Indiscriminate to Valid Testing: Part II," <i>Psychopharmacology</i> , 107:461-473 (1992).	
C213	Sarter, M., "Behavioral Screening for Cognition Enhancers: from Indiscriminate to Valid Testing: Part I," <i>Psychopharmacology</i> , 107:144-158 (1992).	
C214	Satoh, M., <i>et al.</i> , "A Pharmacological Profile of LTP in CA3 Region of Guinea-Pig Hippocampus <i>In Vitro</i> ," <i>Biomedical Research</i> , 10(2):125-129, 1989.	
C215	Schachter, M., <i>et al.</i> , "Deprenyl in the Management of Response Fluctuations in Patients with Parkinson's Disease on Levodopa," <i>J. Neurol., Neurosurg., Psychiatry</i> , 43:1016-1021 (1980).	
C216	Scheinin, H., <i>et al.</i> , "CYP2D6 Polymorphism is Not Crucial for the Disposition of Selegiline," <i>Clin. Pharmacol. Ther.</i> , 64(4):402-411 (1998).	
C217	Shappell, S. A., <i>et al.</i> , "Stimulated Sustained Flight Operations and Performance, Part 2: Effects of Dextro-Methamphetamine," <i>Military Psychology</i> , 4(4), 267-287 (2002).	
C218	Shimada, A., <i>et al.</i> , "Neurochemical Analysis of the Psychotoxicity of Methamphetamine and Cocaine by Microdialysis in the Rat Brain," <i>Ann. N. Y. Acad. Sci.</i> , 801(1):361-370 (1996).	
C219	Shimosato, K., "Urinary Excretion of <i>p</i> -Hydroxylated Methamphetamine Metabolites in Man. II. Effect of Alcohol Intake on Methamphetamine Metabolism," <i>Pharmacol. Biochem. Behav.</i> , 29: 733-740 (1988).	
C220	Shutter, L. and Garell, D. C., "Obesity in Children and Adolescents: A Double-Blind Study with Cross-Over," <i>J. Sch. Health</i> , 273-275 (1966).	
C221	Sim, T., <i>et al.</i> , "Cognitive Deficits Among Methamphetamine Users with Attention Deficit Hyperactivity Disorder Symptomatology," <i>J. Addict. Dis.</i> , 21(1):75-89 (2002).	
C222	Simpson, L. L., "Blood Pressure and Heart Rate Responses Evoked by <i>d</i> - and <i>l</i> -Amphetamine in the Pithed Rat Preparation," <i>J. Pharmacol. Exp. Ther.</i> , 193:149-159 (1975).	
C223	Simpson, L. L., "Evidence That Deprenyl, A Type B Monoamine Oxidase Inhibitor, Is an Indirectly Acting Sympathomimetic Amine," <i>Biochem. Pharmacol.</i> , 27:1591-1595 (1978).	
C224	Smith, R. C., <i>et al.</i> , "Comparative Effects of <i>d</i> -Amphetamine, <i>l</i> -Amphetamine, and Methylphenidate on Mood in Man," <i>Psychopharmacology</i> 53:1-12 (1977).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C225	Soetens, E., <i>et al.</i> , "Effect of Amphetamine on Long-Term Retention of Verbal Material," <i>Psychopharmacology</i> , 119:155-162 (1995).
	C226	Soetens, E., <i>et al.</i> , "Amphetamine Enhances Human-Memory Consolidation," <i>Neurosci. Lett.</i> 161:9-12 (1993).
	C227	Song, J. K., <i>et al.</i> , "Neuroradiologic Diagnosis and Treatment of Vasospasm," <i>Cerebral Aneurysms</i> , 7(4):819-835 (1997).
	C228	Sprague, J. E. and Nichols, D. E., "The Monoamine Oxidase-B Inhibitor L-Deprenyl Protects Against 3,4-Methylenedioxymethamphetamine-Induced Lipid Peroxidation and Long-term Serotonergic Deficits," <i>J. Pharmacol. Exp. Ther.</i> , 273(2):667-673 (1995).
	C229	Squire, L. R., "Cerebral Protein Synthesis Inhibition and Discrimination Training: Effects of D-amphetamine," <i>Brain Res.</i> , 177:401-406 (1999).
	C230	Stein, L., <i>et al.</i> , "Memory Enhancement by Central Administration of Norepinephrine," <i>Brain Res.</i> 84(1):329-335 (1975).
	C231	Strupp, B. J., <i>et al.</i> , "Time-Dependent Effects of Post-Trial Amphetamine Treatment in Rats: Evidence for Enhanced Storage of Representational Memory," <i>Behav. Neural. Biol.</i> , 56:62-76 (1991).
	C232	Szende, B., <i>et al.</i> , "Anti-apoptotic and Apoptotic Action of (-)-deprenyl and its Metabolites," <i>J. Neural. Transm.</i> , 108:25-33 (2001).
	C233	Szoko, E., <i>et al.</i> , "Biotransformation of Deprenyl Enantiomers," <i>Eur. J. Drug Metab. Pharmacokinet.</i> , 24(4):315-319 (1999).
	C234	Tariot, P. N., <i>et al.</i> , "Cognitive effects of L-deprenyl in Alzheimer's Disease," <i>Psychopharmacology</i> , 91:489-495 (1987).
	C235	Tariot, P. N., <i>et al.</i> , "L-Deprenyl in Alzheimer's Disease," <i>Arch. Gen. Psychiatry</i> , 44:427-433 (1987).
	C236	Tatton, W. G., "Selegiline Can Mediate Neuronal Rescue Rather Than Neuronal Protection," <i>Movement Disorder Society</i> , 8(Supp. 1):S20-S30 (1993).
	C237	Teter, D. F., "Metabolism of Diet Pill to Amphetamine and Methamphetamine," (Letters to the Editor), <i>JOEM</i> , 41(3):139 (1999).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3474.1001-011	APPLICATION NO.: 10/791,223	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004
	EXAMINER Not assigned	CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C238	ThyagaRajan, S., <i>et al.</i> , "Region-specific Alterations in the Concentrations of Catecholamines and Indoleamines in the Brains of Young and Old F344 Rats after L-deprenyl Treatment," <i>Brain Res. Bull.</i> , 48(5):513-520 (1999).	
C239	Van Rijzingen, I. M. S., "ACTH(4-9) Analog ORG2766 Treatment 7 Months Delayed Still Improves Morris Maze Performance of Fimbria-Lesioned Rats," <i>Pharmacol. Biochem. Behav.</i> , 53(1):163-169 (1996).	
C240	Van Alvea, O. E., and Donnelly, W. A., "Systemic Effects of Intranasal Medication," <i>Eye, Ear, Nose & Throat Monthly</i> , 31:476-480 (1952).	
C241	Van Kammen, D. P. and Murphy, D. L., "Attenuation of the Euphoriant and Activating Effects of <i>d</i> - and <i>l</i> -Amphetamine by Lithium Carbonate Treatment," <i>Psychopharmacologia (Berl.)</i> , 44:215-224 (1975).	
C242	Vidrio, H., "Cardiovascular Effects of Methamphetamine in Dogs Treated Chronically with the Amine," <i>J. Cardiovas. Pharmacol.</i> , 4(2):326-329 (1982).	
C243	Volkow, N. D., <i>et al.</i> , "Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence," <i>J. Neurosci.</i> , 21(23):9414-9418 (2001).	
C244	Vorhees, C. V., <i>et al.</i> , "Adult Learning Deficits After Neonatal Exposure to D-Methamphetamine: Selective Effects on Spatial Navigation and Memory," <i>J. Neurosc.</i> , 20(12):4732-4739 (2000).	
C245	Vree, T. B., and van Rossum, J. M., "Kinetics of Metabolism and Excretion of Amphetamines in Man," in <i>Amphetamines and Related Compounds</i> , Costa and Garattini, eds. (Rave Press, NY) pp. 165-190 (1970).	
C246	Walter-Batson, D., <i>et al.</i> , "Amphetamine Paired with Physical Therapy Accelerates Motor Recovery After Stroke," <i>Stroke</i> , 26(12):2254-2259 (1995).	
C247	Wan, S. H., <i>et al.</i> , "Kinetics, Salivary Excretion of Amphetamine Isomers, and Effect of Urinary pH," <i>Clin. Pharmacol. Ther.</i> , 23(5):585-590 (1978).	
C248	Wang, J. Q. and McGinty, J. F., "Dose-Dependent Alteration in <i>zif/268</i> and Preprodynorphin mRNA Expression Induced by Amphetamine or Methamphetamine in Rat Forebrain," <i>J. Pharmacol. Exp. Ther.</i> , 273(2):909-917 (1995).	
C249	Wiegmann, D. A., <i>et al.</i> , "Methamphetamine Effects on Cognitive Processing During Extended Wakefulness," <i>Int. J. Aviat. Psychol.</i> , 6(4):379-397 (1996).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned		CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C250	Wilcock, G. K., <i>et al.</i> , "The Effect of Selegiline in the Treatment of People with Alzheimer's Disease: a Meta-analysis of Published Trials," <i>Int. J. Geriatr. Psychiatry</i> 17:175-183 (2002).	
C251	Witkin, J. M. <i>et al.</i> , "Behavioral, Toxic and Neurochemical Effects of Sydnocarb, a Novel Psychomotor Stimulant: Comparisons with Methamphetamine," <i>Pharmacol. Exp. Ther.</i> , 288(3):1298-1310 (1999).	
C252	Wolthuis, O. L., "Experiments With UCB 6215, A Drug Which Enhances Acquisition In Rats: Its Effects Compared With Those of Metamphetamine," <i>Eur. J. Pharmacol.</i> , 16:283-297 (1971).	
C253	Yamamoto, R., and Takasaki, K., "Involvement of Presynaptic α_2 -Adrenoreceptors in the Depressor Response Produced by Repeated Administration of Dextro-Methamphetamine," <i>J. Auton. Pharmac.</i> , 3: 79-88 (1983).	
C254	Yamamura, T., <i>et al.</i> , "Effects of Methamphetamine and Ethanol on Learning and Brain Neurotransmitters in Rats," <i>Pharmacol. Biochem. Behav.</i> , 42:389-400 (1992).	
C255	Yamamura, T., <i>et al.</i> , "Effects of Daily Administration of Methamphetamine on Multiple Active/Passive Avoidance Performance in Rats," <i>Behav. Brain Res.</i> , 53:105-112 (1993).	
C256	Yanagisawa, Y., <i>et al.</i> , "Association Equilibrium of <i>d</i> -Methamphetamine and <i>l</i> -Methamphetamine With Serum Albumin," <i>Chirality</i> 10:742-746 (1998).	
C257	Yasar, S., <i>et al.</i> , "Are Metabolites of I-deprenyl (Selegiline) Useful or Harmful? Indications From Preclinical Research," <i>J. Neurol. Transmission</i> [suppl 48], Springer Verlag, Wein, New York, pp. 61-73 (1996).	
C258	Yasar, S. and Bergman, J., "Amphetamine-like effect of <i>l</i> -deprenyl (selegiline) in Drug Discrimination Studies," <i>Clin. Pharmacol. Ther.</i> , 56(6):768-773 (1994).	
C259	Yasar, S. <i>et al.</i> , "Evaluation of the Stereoisomers of Deprenyl for Amphetamine-Like Discriminative Stimulus Effects in Rats," <i>J. Pharmacol. Exp. Ther.</i> , 265(1):1-6 (1993).	
C260	Yasar, S., <i>et al.</i> , "Preclinical Evaluation of <i>l</i> -Deprenyl: Lack of Amphetamine-Like Abuse Potential," <i>Inhibitors of Monoamine Oxidase B Pharmacology and Clinical Uses in Neurodegenerative Disorders</i> , I. Szelenyi, ed. (Switzerland: Birkhauser Verlag Basel), pp. 215-233 (1993).	
C261	Yi-Ping, H., "Effects of Modafinil and Amphetamine on Sleep-Wake Cycle After Sleep Deprivation in Cats," <i>Acta Pharmacol Sin</i> , 20(9):813-818 (1999).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO.: 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Not assigned	CONFIRMATION NO. 3953	GROUP 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C262	Yokel, R. A. and Pickens, R., "Self-Administration of Optical Isomers of Amphetamine and Methamphetamine by Rats," <i>J. Pharmacol. Exp. Ther.</i> , 187(1):27-33 (1973).
	C263	Yonkov, D. I., "Participation of Cholinergic Mechanisms in The Memory Effects of CNS Stimulants," <i>Advanced In The Bioscience, Pergamon Press, GB.</i> , 59:347-350 (1986).
	C264	Yoshida, T., <i>et al.</i> , "Metabolism of Deprenyl, a Selective Monoamine Oxidase (MAO) B Inhibitor in Rat: Relationship of Metabolism to MAO- β Inhibitory Potency," <i>Xenobiotica</i> , 16(2):129-136 (1986).
	C265	Young, G. A., "Relationship Between Amphetamine-Induced Effects on EEG Power Spectra and Motor Activity in Rats," <i>Pharmacology Biochemistry & Behavior</i> 30:489-492 (1988).
	C266	Yui, K., <i>et al.</i> , "Noradrenergic Activity and Spontaneous Recurrence of Methamphetamine Psychosis," <i>Drug and Alcohol Depend.</i> , 44: 183-187 (1997).
	C267	Yui, K. and Miura, T., "Behavioral Responses Induced by Repeated Treatment with Methamphetamine Alone and in Combination with Scopolamine in Rats," <i>Neuropsychobiology</i> , 33:21-27 (1996).
	C268	Zink, W. E., <i>et al.</i> , "Model Systems for Assessing Cognitive Function: Implications for HIV-1 Infection and Drugs of Abuse," <i>Neuroimmune Circuits, Drugs of Abuse, and Infectious Diseases</i> , 7-27 (2001).

EXAMINER	DATE CONSIDERED
----------	-----------------